(2S)-2-(2-bromoisonicotinoylamino)-3-(3,4-dimethoxyphenyl)-1-propanol | 209262-38-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S)-2-(2-bromoisonicotinoylamino)-3-(3,4-dimethoxyphenyl)-1-propanol
• 英文别名: 2-bromo-N-[(2S)-1-(3,4-dimethoxyphenyl)-3-hydroxypropan-2-yl]pyridine-4-carboxamide
• CAS: 209262-38-4
• 化学式: C₁₇H₁₉BrN₂O₄
• 分子量: 395.253
• InChiKey: PBUNFYVLZYRSRN-ZDUSSCGKSA-N

物化性质

• 沸点：
  592.609±50.00 °C(Press: 760.00 Torr)(predicted)
• 密度：
  1.418±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  80.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2S)-2-(2-bromoisonicotinoylamino)-3-(3,4-dimethoxyphenyl)-1-propanol 在 lithium hydroxide 、 copper(l) iodide 、 potassium carbonate 、 三乙胺 、 三氯氧磷 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 2-[4-[(3S)-3-(hydroxymethyl)-6,7-dimethoxy-3,4-dihydroisoquinolin-1-yl]pyridin-2-yl]-4-(pyridin-3-ylmethyl)phthalazin-1-one
  参考文献：
  名称：

  Synthesis and biological activities of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives as PDE4 inhibitors

  摘要：

  A novel series of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives has been prepared. These compounds showed potent PDE4 inhibitory activities and a broad margin between the K-i value of the rolipram binding affinity and the IC50 value of PDE4 inhibition. They also exhibited potent inhibitory activities toward LPS-induced TNF-alpha production in mice. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00438-4
• 作为产物：
  描述：

  2-溴-4-吡啶羧酸 在 甲醇 、 sodium tetrahydroborate 、 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 (2S)-2-(2-bromoisonicotinoylamino)-3-(3,4-dimethoxyphenyl)-1-propanol
  参考文献：
  名称：

  Synthesis and biological activities of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives as PDE4 inhibitors

  摘要：

  A novel series of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives has been prepared. These compounds showed potent PDE4 inhibitory activities and a broad margin between the K-i value of the rolipram binding affinity and the IC50 value of PDE4 inhibition. They also exhibited potent inhibitory activities toward LPS-induced TNF-alpha production in mice. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00438-4

文献信息

• Pyridine derivatives
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：US05965730A1

  公开（公告）日：1999-10-12

  A pyridine derivative of the formula (I): ##STR1## wherein A is group of the following formulae: ##STR2## (R.sup.1 and R.sup.2 are each H, or protected or unprotected OH, R.sup.31, R.sup.41 and R.sup.42 are protected or unprotected hydroxymethyl, R.sup.32 is H, lower alkyl, or protected or unprotected hydroxymethyl, R.sup.33 is substituted or unsubstituted lower alkyl, and the dotted line means the presence or absence of a double bond), R.sup.5 and R.sup.6 are H, or protected or unprotected amino, or both combine together with the adjacent nitrogen to form substituted or unsubstituted heterocycle, or a pharmaceutically acceptable salt thereof, these compounds showing excellent bronchoconstriction inhibitory activity and/or anti-inflammatory activity of airway, and being useful in the prophylaxis or treatment of asthma.

  化合物的化学式（I）的吡啶衍生物：其中A是以下化学式的基团：（R.sup.1和R.sup.2分别为H，或受保护或未受保护的OH，R.sup.31、R.sup.41和R.sup.42为受保护或未受保护的羟甲基，R.sup.32为H，较低的烷基，或受保护或未受保护的羟甲基，R.sup.33为取代或未取代的较低烷基，虚线表示双键的存在或不存在），R.sup.5和R.sup.6为H，或受保护或未受保护的氨基，或两者结合在一起与相邻的氮形成取代或未取代的杂环，或其药学上可接受的盐，这些化合物表现出出色的支气管收缩抑制活性和/或气道抗炎活性，并且在哮喘的预防或治疗中有用。
• Pharmaceutical pyridine derivatives, processes for preparing the same and intermediates therefor
  申请人：TANABE SEIYAKU CO., LTD.

  公开号：EP0848000A1

  公开（公告）日：1998-06-17

  A pyridine derivative of the formula (I): wherein A is group of the following formulae: R1 and R2 are each H, or protected or unprotected OH, R31, R41 and R42 are protected or unprotected hydroxymethyl, R32 is H, lower alkyl, or protected or unprotected hydroxymethyl, R33 is substituted or unsubstituted lower alkyl, and the dotted line means the presence or absence of a double bond' R5 and R6 are H, or protected or unprotected amino, or both combine together with the adjacent nitrogen to form substituted or unsubstituted heterocycle, or a pharmaceutically acceptable salt thereof, show excellent bronchoconstriction inhibitory activity and/or anti-inflammatory activity of airways, and are , useful in the prophylaxis or treatment of asthma.

  式（I）的吡啶衍生物： 其中 A 为下式中的基团： R1 和 R2 分别为 H，或受保护或未受保护的 OH，R31、R41 和 R42 为受保护或未受保护的羟甲基，R32 为 H、低级烷基或受保护或未受保护的羟甲基，R33 为取代或未取代的低级烷基，虚线表示存在或不存在双键' R5 和 R6 为 H、或受保护或未受保护的氨基，或两者与相邻的氮结合在一起形成取代或未取代的杂环，或其药学上可接受的盐，显示出优异的支气管收缩抑制活性和/或气道抗炎活性，可用于预防或治疗哮喘。
• US5965730A
  申请人：——

  公开号：US5965730A

  公开（公告）日：1999-10-12
• Synthesis and biological activities of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives as PDE4 inhibitors
  作者：Tatsuzo Ukita、Masakatsu Sugahara、Yoshihiro Terakawa、Tooru Kuroda、Kazuteru Wada、Aya Nakata、Hideo Kikkawa、Katsuo Ikezawa、Kazuaki Naito

  DOI：10.1016/s0960-894x(03)00438-4

  日期：2003.7

  A novel series of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives has been prepared. These compounds showed potent PDE4 inhibitory activities and a broad margin between the K-i value of the rolipram binding affinity and the IC50 value of PDE4 inhibition. They also exhibited potent inhibitory activities toward LPS-induced TNF-alpha production in mice. (C) 2003 Elsevier Science Ltd. All rights reserved.